Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | HTR5A | P47898 | 1/20 | 0.30 |
| ▸ | OXTR | P30559 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17344768 | 0.80 | ALOX15 (0.32) | ALOX15HSD17B10 | |
| SCHEMBL17344786 | 0.77 | MAPT (0.34) | GAAMAOAMAOBHTR5AOXTR | |
| SCHEMBL17344792 | 0.77 | GAA (0.50) | ALOX15HSD17B10GAANPSR1MAOA | |
| SCHEMBL17348453 | 0.68 | ALOX15 (0.38) | ALOX15HSD17B10HSD17B3GAANPSR1 | |
| SCHEMBL17344796 | 0.68 | CA12 (0.47) | ALOX15HSD17B10GAANPSR1CA12 | |
| SCHEMBL20364329 | 0.67 | MAOB (0.47) | ALOX15HSD17B10HSD17B3GAANPSR1 | |
| SCHEMBL14084320 | 0.66 | GAA (0.63) | ALOX15HSD17B10HSD17B3GAANPSR1 | |
| SCHEMBL12147340 | 0.62 | — | — | |
| SCHEMBL29580106 | 0.61 | OXTR (0.67) | HSD17B3GAANPSR1MAOAMAOB | |
| SCHEMBL19823618 | 0.60 | ALOX15 (0.37) | ALOX15HSD17B10MAOAMAOBCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150361093-A1 | HIV REPLICATION INHIBITOR | SHIONOGI & CO., LTD. (JP) | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361093-A1 | HIV REPLICATION INHIBITOR | RTF2, REV1, PCNA | ALOX15 3858/4885HSD17B10 2053/4885HSD17B3 2572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.